The Effect of Epiretinal Membrane on Intravitreal Anti-Vegf Treatment in Diabetic Macula Edema
No Thumbnail Available
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Purpose: In the study we aimed to investigate effect of concomitant epiretinal membrane on results of anti-VEGF treatment in diabetic
macular edema.
Materials and Methods: In the study we included patients with epiretinal membrane and diabetic macular edema who were followed in
the retina unit. Patients received initial loading doses of three injections; followed by 0.5 mg/month ranibizumab injections as needed.
In all patients, central macular thickness, optical coherence tomography fi ndings and best-corrected visual acuity were evaluated.
RESULTS: The study included 31 eyes of 37 patients (4 patients received bilateral treatment). The mean age of the patients was
62.4±7.4 years. The patients received an average of 3.9 doses of ranibizumab injection. In the study, 12 (38%) of 31 eyes underwent
cataract surgery. The mean central macular thickness (CMT) was 429.25±127.41μm at baseline and 324.42±69.74 at the end of
treatment (p< 0.01). The mean BCVA (logMAR) was determined as 0.64±0.34 at baseline and 0.50±0.27 after the treatment (p< 0.01).
No signifi cant differences were found in the CMT and BCVA between genders (p> 0.05).
Conclusion: It was found that anti-VEGF (ranibizumab) treatment provided signifi cant improvement on CMT and BCVA (logMAR)
values in cases with diabetic macular edema and epiretinal membrane